Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Furthermore, Eli Lilly’s pipeline in immunology and neuroscience also holds promise. Recent approvals like Omvoh for Crohn’s disease and ongoing development in areas like atopic dermatitis ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Eli Lilly and Company discovers ... and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

That is the kind of half-joking question that doctors kick around when a new class of drugs begins to help a big chunk of the ...